Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cancer immunotherapy in patients with brain metastases

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{ebddd94c9cd54427968d06efb7d42243,
title = "Cancer immunotherapy in patients with brain metastases",
abstract = "The exclusion of {"}real-world{"} patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a {"}real-world{"} setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.",
author = "Salvatore Caponnetto and Arianna Draghi and Borch, {Troels Holz} and Marianna Nuti and Enrico Cortesi and Svane, {Inge Marie} and Marco Donia",
year = "2018",
month = "5",
doi = "10.1007/s00262-018-2146-8",
language = "English",
volume = "67",
pages = "703--711",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Cancer immunotherapy in patients with brain metastases

AU - Caponnetto, Salvatore

AU - Draghi, Arianna

AU - Borch, Troels Holz

AU - Nuti, Marianna

AU - Cortesi, Enrico

AU - Svane, Inge Marie

AU - Donia, Marco

PY - 2018/5

Y1 - 2018/5

N2 - The exclusion of "real-world" patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a "real-world" setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.

AB - The exclusion of "real-world" patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a "real-world" setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.

U2 - 10.1007/s00262-018-2146-8

DO - 10.1007/s00262-018-2146-8

M3 - Review

VL - 67

SP - 703

EP - 711

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 5

ER -

ID: 54806559